Cargando…

The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy

Immune checkpoint inhibitors have revolutionized treatment and outcome of melanoma and many other solid malignancies including non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Unfortunately, only a minority of patients have a long-term benefit, while the remaining demonstrate prima...

Descripción completa

Detalles Bibliográficos
Autores principales:	Botticelli, Andrea, Cirillo, Alessio, Scagnoli, Simone, Cerbelli, Bruna, Strigari, Lidia, Cortellini, Alessio, Pizzuti, Laura, Vici, Patrizia, De Galitiis, Federica, Di Pietro, Francesca Romana, Cerbelli, Edoardo, Ghidini, Michele, D’Amati, Giulia, Della Rocca, Carlo, Mezi, Silvia, Gelibter, Alain, Giusti, Raffaele, Cortesi, Enrico, Ascierto, Paolo Antonio, Nuti, Marianna, Marchetti, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349154/ https://www.ncbi.nlm.nih.gov/pubmed/32353934 http://dx.doi.org/10.3390/vaccines8020203

Ejemplares similares

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
por: Botticelli, Andrea, et al.
Publicado: (2021)

The role of opioids in cancer response to immunotherapy
por: Botticelli, Andrea, et al.
Publicado: (2021)

Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer
por: Mezi, Silvia, et al.
Publicado: (2021)

Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1
por: Botticelli, Andrea, et al.
Publicado: (2020)

Circulating CD137(+) T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients
por: Cirillo, Alessio, et al.
Publicado: (2023)

The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study
por: Botticelli, Andrea, et al.
Publicado: (2021)

Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer
por: Cerbelli, Bruna, et al.
Publicado: (2020)

The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial
por: Botticelli, Andrea, et al.
Publicado: (2020)

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
por: Botticelli, Andrea, et al.
Publicado: (2017)

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
por: Botticelli, Andrea, et al.
Publicado: (2019)

The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy
por: Botticelli, Andrea, et al.
Publicado: (2022)

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
por: Marchetti, Paolo, et al.
Publicado: (2020)

Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer
por: Gelibter, Alain, et al.
Publicado: (2020)

Genomic and Immune Approach in Platinum Refractory HPV-Negative Head and Neck Squamous Cell Carcinoma Patients Treated with Immunotherapy: A Novel Combined Profile
por: Mezi, Silvia, et al.
Publicado: (2022)

PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
por: Cerbelli, Bruna, et al.
Publicado: (2017)

Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era
por: Botticelli, Andrea, et al.
Publicado: (2021)

Circulating CD137(+) T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2022)

Immune effects of CDK4/6 inhibitors in patients with HR(+)/HER2(−) metastatic breast cancer: Relief from immunosuppression is associated with clinical response
por: Scirocchi, Fabio, et al.
Publicado: (2022)

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
por: Botticelli, Andrea, et al.
Publicado: (2018)

The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
por: Mezi, Silvia, et al.
Publicado: (2023)

Overexpression in metastatic breast cancer supports Syndecan-1 as a marker of invasiveness and poor prognosis
por: Cerbelli, Bruna, et al.
Publicado: (2022)

Atypical cellular neurothekeoma (ACN) of the elderly: case report and brief review of the literature
por: D’Alessandris, Nicoletta, et al.
Publicado: (2020)

Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?
por: Botticelli, Andrea, et al.
Publicado: (2016)

Primary squamous cell carcinoma of major salivary gland: “Sapienza Head and Neck Unit” clinical recommendations
por: Mezi, Silvia, et al.
Publicado: (2020)

The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature
por: Botticelli, Andrea, et al.
Publicado: (2022)

Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach
por: Botticelli, Andrea, et al.
Publicado: (2023)

Radiologic-pathologic correlation in breast cancer: do MRI biomarkers correlate with pathologic features and molecular subtypes?
por: Galati, Francesca, et al.
Publicado: (2022)

Results of Adrenalectomy for Isolated, Metachronous Metastasis of Breast Cancer: A Retrospective Cohort Study
por: Illuminati, Giulio, et al.
Publicado: (2021)

Small hepatic veins Budd-Chiari syndrome and paroxysmal nocturnal hemoglobinuria - The association of two rare entities: a case report
por: Gioia, Stefania, et al.
Publicado: (2020)

Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
por: Botticelli, Andrea, et al.
Publicado: (2020)

Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology
por: Valentini, Virginia, et al.
Publicado: (2023)

Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer
por: Borro, Marina, et al.
Publicado: (2016)

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2019)

Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2020)

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment
por: Botticelli, Andrea, et al.
Publicado: (2016)

IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137(+)T-cells
por: Ugolini, Alessio, et al.
Publicado: (2020)

Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2020)

Pathological examination of breast cancer samples before and after neoadjuvant therapy: recommendations from the Italian Group for the Study of Breast Pathology - Italian Society of Pathology (GIPaM-SIAPeC)
por: Fusco, Nicola, et al.
Publicado: (2022)

Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario
por: Trevisani, Francesco, et al.
Publicado: (2022)

A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumors
por: Mezi, Silvia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lq1ugrhqp7l0csm9hpu33agm6i